Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

A new study finds that combining the COVID vaccine with immunotherapy may nearly double cancer survival rates — patients ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...

Comparable overall survival seen at seven and 10 years, lung cancer-specific survival, and recurrence-free survival.

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

5-year overall survival (OS) rate for stereotactic body radiation ... body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors =2 cm" in the ...